Please provide your email address to receive an email when new articles are posted on . Combined cataract surgery with iStent inject significantly reduced medication burden in patients with glaucoma.

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and ...

Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with glaucoma, expanding the company’s reach overseas. The green lights under ...

FDA has announced it has approved the first glaucoma stent for use with cataract surgery, according to a news release. The iStent Trabecular Micro-Bypass Stent System, model GTS100R/L, manufactured by ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted 510(k) clearance for the iStent infinite trabecular micro-bypass system to reduce IOP as a stand ...

Novel Three-Stent Injectable System Designed to Provide Foundational, 24/7 IOP Control ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and ...

Glaukos has secured European Union Medical Device Regulation (EU-MDR) certification for its iStent infinite, along with other micro-invasive glaucoma surgery (MIGS) technologies, including the iStent ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

San Clemente-based Glaukos Corp. anticipates strong revenue growth next year for its iStent products, based on a guarantee of reimbursement on procedures that use its iStent implant. Glaukos expects ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...